Baricitinib (Compound)

Synonyms:Baricitinib, 1187594-09-7, olumiant, INCB028050, LY3009104, INCB 028050, 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile, INCB-028050, LY-3009104, Baricitinib [USAN:INN], 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile, UNII-ISP4442I3Y, ISP4442I3Y, LY 3009104, Baricitinib (LY3009104, INCB028050), 2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE, 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-, LY3009104 (phosphate);INCB028050 (phosphate), INCB28050, Baricitinib [USAN], INCB 28050, Olumiant (TN), 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-, 3JW, BARICITINIB [MI], BARICITINIB [INN], BARICITINIB [JAN], BARICITINIB [WHO-DD], MLS006011247, SCHEMBL871150, Baricitinib (JAN/USAN/INN), Baricitinib (LY3009104), BARICITINIB [EMA EPAR], Baricitinib (INCB028050), GTPL7792, CHEMBL2105759, CHEBI:95341, BARICITINIB [ORANGE BOOK], DTXSID30152228, EX-A413, HMS3651L17, HMS3672M15, HMS3747G21, BCP04686, BDBM50021656, MFCD21608464, NSC799357, s2851, AKOS022186127, AKOS025401933, AM81232, BCP9000380, CCG-268312, CS-0724, DB11817, DS-7641, NSC-799357, PB27275, SB10845, NCGC00345839-01, NCGC00345839-14, NCGC00345839-16, 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile, AC-27404, HY-15315, SMR004703006, BCP0726000031, Baricitinib (INCB28050, LY3009104), FT-0775037, SW220096-1, D10308, A892931, EN300-24435973, J-503551, Q4860707, Z2724205326, (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile, 2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile, INCB 28050; INCB28050; LY-3009104;1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile

Pubchem:PUBCHEM:44205240

Id:94759ed9-0a82-546b-9710-283d0545f9a0

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Baricitinib's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Baricitinib.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Baricitinib.

Results found

Linked to

	Label	Description
	BRD-K53581288-001-02-9 Substance (Entity type)	A Substance
	DCSTRUCT ID 05202 Collection (Entity type)	DrugPage Collection: (DrugCentralID:05202; PubChem_CID:44205240, FILE=drugcentral_drug_05202.json)
	baricitinib (cf69a004-c862-4424-9b86-28eeef176921) Collection (Entity type)	Metadatata for baricitinib
	Baricitinib positively regulates LUM Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Baricitinib positively regulates S100A8 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Baricitinib positively regulates NKX3-1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Baricitinib positively regulates NIBAN1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Baricitinib negatively regulates GOLGA8H Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Baricitinib negatively regulates MX1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Baricitinib negatively regulates APOD Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS